Category
All
New Technology
Service & Software
Internet & Communication
Electronics & Semiconductor
Pharma & Healthcare
Other
Energy & Power
Agriculture
Consumer Goods
Machinery & Equipment
Food & Beverages
Medical Care
Automobile & Transportation
Packaging
Chemical & Material
Medical Devices & Consumables
Category
All
Total: 3 records, 1 pages
Search For: gene therapy for ovarian cancer
Global Gene Therapy for Ovarian Cancer Market 2024 by Company, Regions, Type and Application, Forecast to 2030
26 Jan 2024
Medical Care
Gene Therapy for Ovarian Cancer
According to our (Global Info Research) latest study, the global Gene Therapy for Ovarian Cancer market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
USD3480.00
Add To Cart
Global Gene Therapy for Ovarian Cancer Supply, Demand and Key Producers, 2023-2029
06 Mar 2023
Medical Care
Gene Therapy for Ovarian Cancer
Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor, and stromal ovarian tumor are some of the less common types. It is the seventh most common cancer in women globally and 18th most common cancer overall. The ovarian cancer immunotherapies market has already got some commercially successful chemotherapy products. However, chemotherapy often involves a combination of two or more drugs, given intravenously every 3-4 weeks, and mostly associated with long-lasting side/adverse effects. Various studies have shown that chemotherapy can damage the blood-producing cells of the bone marrow, resulting in blood-related complications.
USD4480.00
Add To Cart
Global Gene Therapy for Ovarian Cancer Market 2023 by Company, Regions, Type and Application, Forecast to 2029
03 Jan 2023
Medical Care
Gene Therapy for Ovarian Cancer
Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor, and stromal ovarian tumor are some of the less common types. It is the seventh most common cancer in women globally and 18th most common cancer overall. The ovarian cancer immunotherapies market has already got some commercially successful chemotherapy products. However, chemotherapy often involves a combination of two or more drugs, given intravenously every 3-4 weeks, and mostly associated with long-lasting side/adverse effects. Various studies have shown that chemotherapy can damage the blood-producing cells of the bone marrow, resulting in blood-related complications.
USD3480.00
Add To Cart
Popular Product Keywords
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
Search For: gene therapy for ovarian cancer
Total: 3 records, 1 pages
According to our (Global Info Research) latest study, the global Gene Therapy for Ovarian Cancer market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
USD3480.00
Add To Cart
Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor, and stromal ovarian tumor are some of the less common types. It is the seventh most common cancer in women globally and 18th most common cancer overall. The ovarian cancer immunotherapies market has already got some commercially successful chemotherapy products. However, chemotherapy often involves a combination of two or more drugs, given intravenously every 3-4 weeks, and mostly associated with long-lasting side/adverse effects. Various studies have shown that chemotherapy can damage the blood-producing cells of the bone marrow, resulting in blood-related complications.
USD4480.00
Add To Cart
Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor, and stromal ovarian tumor are some of the less common types. It is the seventh most common cancer in women globally and 18th most common cancer overall. The ovarian cancer immunotherapies market has already got some commercially successful chemotherapy products. However, chemotherapy often involves a combination of two or more drugs, given intravenously every 3-4 weeks, and mostly associated with long-lasting side/adverse effects. Various studies have shown that chemotherapy can damage the blood-producing cells of the bone marrow, resulting in blood-related complications.
USD3480.00
Add To Cart
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
-
Insight into the industry market information
-
Analyze market development needs
-
Prospects for future development
-
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>